Trial Profile
EVOLVD: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Acronyms EVOLVD
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 26 Aug 2023 According to an Amgen media release, data this study of olpasiran, presented in a late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam.
- 20 May 2022 Planned End Date changed from 1 Jan 2022 to 20 May 2023.